Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study

Area of Science:

• Pediatrics
• Neurology
• Rehabilitation Medicine

Background:

• Adductor spasticity is a common challenge in children with cerebral palsy (CP).
• This condition significantly impairs motor function and overall development.
• Effective management strategies are crucial for improving quality of life.

Purpose of the Study:

• To evaluate the efficacy of botulinum toxin A (BTX-A) in treating adductor spasticity in pediatric CP patients.
• To compare BTX-A treatment against a placebo in a randomized, double-blind, multicenter setting.
• To assess the impact of BTX-A on key measures of spasticity and functional goals.

Main Methods:

• A placebo-controlled, double-blind, randomized multicenter study.
• Involved 61 children diagnosed with cerebral palsy (CP) across various GMFCS levels.
• Treatment efficacy was assessed using the knee-knee distance 'fast catch', Ashworth scale, and Goal Attainment Scale.

Main Results:

• Botulinum toxin A (BTX-A) demonstrated significant superiority over placebo.
• Key outcome measures, including knee-knee distance (p=0.002) and Ashworth scale (p=0.001), showed marked improvement.
• The Goal Attainment Scale also indicated significant positive effects (p=0.037) four weeks post-treatment.

Conclusions:

• Botulinum toxin A (BTX-A) is an effective treatment for reducing adductor spasticity in children with cerebral palsy (CP).
• The study confirms BTX-A's ability to improve motor function and achieve functional goals.
• BTX-A represents a valuable therapeutic option for managing spasticity in this population.